News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 02 - 27

Monthly Health Digest | February 2026

Preface:Spring breezes blow strong as we spur our horses forward. Riding the momentum of the 2026 Spring Festival (Year of the Horse), Efung Capital received a series of good news this month: Insight Lifetech successfully listed on the Sci-Tech Innovation Board (STAR Market); three portfolio companies simultaneously advanced their Hong Kong IPOs, with all applications accepted for review.Meanwhile, more portfolio companies have achieved multi-point breakthroughs and advanced together in key sectors, writing a new chapter for China's biopharmaceutical industry with vigorous momentum.&#...

浏览次数：4

查看详情>>

发布时间: 2026 - 02 - 25

Dashi Pharmaceuticals Enters Exclusive Licensing Agreement with Slate Medicines for DS009

Dashi Pharmaceuticals (Guangdong) Co., Ltd. (“Dashi Pharmaceuticals”) today announced that it has entered into an exclusive licensing agreement with Slate Medicines, Inc., a U.S.-based biopharmaceutical company. Under the agreement, Slate Medicines will obtain the exclusive global rights (excluding Greater China) for the clinical development and commercialization of DS009 (to be named SLTE-1009 by Slate Medicines), a potentially best-in-class anti-pituitary adenylate cyclase-activating polypeptide (PACAP) monoclonal antibody independently developed by Dashan Pharmaceuticals. This antibody is i...

浏览次数：2

查看详情>>

发布时间: 2026 - 02 - 10

Trinmab’s RSV Antibody Retavibart Submitted for Approval in China

On February 9, the CDE website indicated that Trinmab’s Retavibart (TNM001) has been submitted for marketing approval for the prevention of lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in infants up to one year of age, including those at high risk for severe RSV infection. This is the second domestic RSV antibody to be considered for priority review, following Ruiyang Pharmaceutical’s Clesrovimab, which was granted priority review just last month.Retavibart is a fully human monoclonal antibody that targets a highly conserved epitope on the pre-fusion (P...

浏览次数：1

查看详情>>

发布时间: 2026 - 02 - 05

Beyond Nanshan's Trillion GDP: Longhua's First Shot on the 2026 STAR Market

IntroductionOn February 5, 2026, Insight Lifetech officially listed on the Sci-Tech Innovation Board (STAR Market).On January 30, 2026, the Nanshan District Statistics Bureau released the main economic indicators for Nanshan District for January–December 2025. According to the unified results of Shenzhen's Gross Domestic Product, Nanshan District's GDP for 2025 reached 1,010.238 billion RMB, representing a year-on-year growth of 6.3% at constant prices, capturing national attention.Under the dazzling spotlight on Nanshan, another dynamic area of Shenzhen—Longhua District—is quietly ris...

浏览次数：2

查看详情>>